drugset / Trial / NCT00159653

A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma

NCT00159653

Phase 3 Completed 500 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.

Timeline

Start
2005-07
Primary completion
2007-06
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Latanoprost Small molecule
Subject Timolol Other / unclassified